This paper is only available as a PDF. To read, Please Download here.
Mammography remains the diagnostic test of choice for breast cancer, but 20% of cancers still go undetected. Many serum biomarkers have been reported for breast cancer but none have proven to represent effective diagnostic strategies. ProteinChip® mass spectrometry is an innovative technology that searches the proteome for differentially expressed proteins, allowing for the creation of a panel or profile of biomarkers. The objective of this study was to construct unique cancer-associated serum profiles that, combined with a classification algorithm, would enhance the detection of breast cancer. Pretreatment serum samples from 134 female patients (45 with cancer, 42 with benign disease, 47 normal) were procured prospectively following institutional review board—approved protocols. Proteins were denatured, applied onto ProteinChip® affinity surfaces, and subjected to surface enhanced laser desorption/ionization (SELDI) time-of-flight mass spectrometry. The SELDI output was analyzed using Biomarker Pattern Software to develop a classification tree based on group-specific protein profiles. The cross-validation analysis of cancer versus normal revealed sensitivity and specificity rates of 80% and 79%, and for cancer versus benign disease, 78% and 83%, respectively. When 2 different chip surfaces were combined the sensitivity and specificity increased to 90% and 93%, respectively. The sensitivity and specificity of this technique are comparable to those of mammography and, if confirmed in a larger study, this technique could provide the means toward development of a simple blood test to aid in the early detection of breast cancer. The combination of SELDI ProteinChip® mass spectrometry and a classification- and regression-tree algorithm has the potential to use serum protein expression profiles for detection and diagnosis of breast cancer.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Clinical Breast Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Evaluation of a palpable breast mass.N Engl J Med. 1992; 327: 937-942
- 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.J Clin Oncol. 2001; 19: 1865-1878
- Assessing the clinical impact of prognostic factors: when is “statistically significant” clinically useful?.Breast Cancer Res Treat. 1998; 52: 305-319
- Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry.Electrophoresis. 2000; 21: 1164-1177
- Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine.Am J Pathol. 2001; 158: 1491-1502
- Generation of a baculovirus recombinant prostate-specific membrane antigen and its use in the development of a novel protein biochip quantitative immunoassay.Protein Expr Purif. 2000; 19: 12-21
- Protein profiling of seminal plasma using Ciphergan's SELDI protein chip technology for early detection of prostate cancer.Proc Am Assoc Cancer Res. 2001; 42 (Abstract #762).: 142
- Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease.Cancer Res. 2001; 61: 6029-6033
- Proteinchip(R) surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures.Prostate Cancer Prostatic Dis. 1999; 2: 264-276
- Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry.Clin Cancer Res. 2002; 8: 2541-2552
Vlahou A, Schorge JO, Gregory BW, et al. Diagnosis of ovarian cancer using decision tree-classification of mass spectral data. J Biomed Biotechnol. In press.
- Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men.Cancer Res. 2002; 62: 3609-3614
- Rapid protein profiling of cancer progression directly from human tissue using a protein biochip.Drug Dev Res. 2000; 49: 34-42
- Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: Potential for new biomarkers to aid in the diagnosis of breast cancer.Dis Markers. 2001; 17: 301-307
- Boosted decision tree analysis of surface- enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients.Clin Chem. 2002; 48: 1835-1843
- Use of proteomic patterns in serum to identify ovarian cancer.Lancet. 2002; 359: 572-577
- Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer.Clin Chem. 2002; 48: 1296-1304
- Ten-year risk of false positive screening mammograms and clinical breast examinations.N Engl J Med. 1998; 338: 1089-1096
- The effect of age and density of the breast on the sensitivity of breast cancer diagnostic by mammography and ultasonography.Breast Cancer Res Treat. 2001; 67: 117-123
Accepted: July 30, 2003
Received in revised form: July 28, 2003
Received: June 23, 2003
© 2003 Elsevier Inc. Published by Elsevier Inc. All rights reserved.